Intellia Therapeutics is seeking FDA approval for its drug Lonvo-Z.
1 report, 1 independent
Updated Sep 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Intellia Therapeutics is seeking FDA approval for its drug Lonvo-Z.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Intellia Therapeutics
It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.
Nothing else this week.
Related events
- Intellia Therapeutics announced it will present at a conference on September 4, 2026.
- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.
- Experimental therapies require approval from the FDA.